Navigation Links
Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses

HARTFORD, Conn., Sept. 13 /PRNewswire/ -- Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

Andreas Windemuth, Ph.D., Chief Technology Officer and co-inventor in the patent stated: "The PhyzioGenomics Technology has been successfully applied to several psychiatric and diabetes drugs and to brain imaging. The technology correlates genotypes and phenotypes in patient populations to discover clinically functional variability. The PhyzioGenomics Technology integrates a biomedical engineering systems approach with genome probes and nano-arrays."

Research on the PhyzioGenomics Technology has been published in the renowned journals Annals of Biomedical Engineering, Biomedical Engineering Handbook, Clinica Chimica Acta, Clinics in Laboratory Medicine, Molecular Psychiatry, Muscle & Nerve, Personalized Medicine, Pharmacogenomics, and Schizophrenia Research.

Gualberto Ruano, M.D., Ph.D., President of Genomas and co-inventor commented: "This fundamental patent covers also the configuration of our products and pipeline, the PhyzioTypeTM Systems. This is a landmark achievement for Genomas and allows us freedom to operate in our industry sector. In an otherwise crowded genomics landscape, and in the presence of an ever more stringent yardstick on novelty versus prior art, this patent significantly increases the value of our intellectual property portfolio and differentiates our proprietary PhyzioType products."

Filed in 2006, US Patent 7,747,392 comprises 23 methods claims and 384 polymorphic DNA sequences representative of 222 key cardiometabolic and neuroendocrine genes. Beyond this patent, the Intellectual Property portfolio of Genomas encompasses 5 patent applications, 2 trademarks, and a copyright on the company's clinical informatics system.


Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary PhyzioType™ Systems for DNA-guided management and prescription of drugs used to treat mental illness and diabetes. PhyzioType Systems provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.

The company's clinical pharmacogenetic tests and consultation service are provided through its Laboratory of Personalized Health, an accredited and licensed high-complexity molecular diagnostic center and its Personalized Health Portal, a medical informatics interface for clinician decision support. Visit for more information.

SOURCE Genomas
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
2. Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association
3. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
4. Genomas to Present at Life Sciences & Healthcare Venture Summit
5. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
6. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
7. Isolux Corsan Awarded a Contract for the Construction of an Ethanol Plant in Colombia
8. Laser pioneer Federico Capasso awarded Berthold Leibinger Zukunftspreis
9. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
10. Flad Architects Awarded Livermore Valley Open Campus Master Plan
11. Colorado State University student awarded top student prize in laser research
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions ... in five states to develop and pitch their BIG ideas to improve health and ... are competing for votes to win the title of SAP's Teen Innovator, an all-expenses ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... , October 27, 2015 ... Semantic Gaze Mapping technology (ASGM) automatically maps data from ... Tracking Glasses , so that they can be ... --> Munich, Germany , October 28-29, ... maps data from mobile eye tracking videos created with ...
(Date:10/23/2015)... Oct. 23, 2015 Research and Markets ( ... "Global Voice Recognition Biometrics Market 2015-2019" report to ... --> The global voice recognition biometrics market to ... --> --> The ... prepared based on an in-depth market analysis with inputs ...
Breaking Biology News(10 mins):